HealthTech M&A Multiples October 2025: Current Trends and Variables driving valuations

The HealthTech M&A market in October 2025 is defined by a "flight to quality" and a bifurcation of valuations, with premiums overwhelmingly concentrated in AI-driven and strategically aligned assets.

M&A activity is steady, driven by significant private equity "dry powder" and strategic buyers seeking efficiency gains and proprietary technology.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email [email protected]

Current M&A Valuation Multiples (Q4 2025)

The general average multiples are misleading due to the massive premium paid for high-growth, high-margin, and highly defensible assets.

EV/Revenue > 4.0x – 6.0x (Average of Q1 2025: 4.8x)

EV/EBITDA > 10.0x – 14.0x (For profitable companies)

Key Trends Driving Multiples

1. AI Integration & Innovation > Highest Premium (6x-8x+ Revenue)

Buyers are paying a premium for proprietary AI algorithms (especially in diagnostics and predictive analytics) that demonstrate proven clinical validation and potential for significant cost reduction

2. Shift to Value-Based Care (VBC)  > Premium (5.5x – 7.0x Revenue)

Solutions enabling the VBC shift (e.g., remote monitoring, population health analytics) are highly valued because they deliver measurable cost savings and improved patient outcomes, a top priority for payers and providers.

3. Recurring Revenue & Scalability > Premium Tied to ARR (6x – 20x ARR)

Like general SaaS companies, HealthTech with high Annual Recurring Revenue (ARR), strong growth trajectories, and high gross margins are favored. Recurring revenue is seen as highly defensible.

4. "Flight to Quality" > Concentration of Capital

Investors are shifting away from aggressive expansion toward a "selective scale" model, favoring later-stage companies with established revenue, clear paths to profitability, and a low Customer Acquisition Cost (CAC).

Key Variables Driving Valuations

The difference between a company valued at 4.0x revenue and one at 8.0x is determined by several core variables:

1. Defensibility and Intellectual Property (IP)

Proprietary Technology: The presence of unique IP, patents, or proprietary datasets that create a strong competitive moat is a major value-driver.

"Workflow Lock-in": Solutions that are deeply integrated into existing clinical or administrative workflows (e.g., EHR systems) create high switching costs for buyers, significantly boosting valuation.

2. Financial Quality

Gross Margin: Companies with high gross margins are valued at a premium, as they indicate greater pricing power and efficient service delivery (especially prevalent in software-only solutions).

Profitability/Path to Profitability: In the current climate, proven profitability (reflected in the $10.0x–14.0x EV/EBITDA range) is a baseline requirement for premium valuations. Unprofitable firms must present a credible, near-term path to positive earnings.

3. Regulatory Clarity (EU AI Act & EHDS)

The European regulatory landscape is becoming a critical value driver:

EU AI Act Compliance: The implementation of the EU AI Act (with compliance rules applicable starting from early 2025) places most healthcare AI tools into the "high-risk" category. Companies that have proactively achieved or demonstrated a clear plan for compliance with the Act's data governance, documentation, and human oversight requirements are seen as lower risk and command higher multiples.

European Health Data Space (EHDS): Companies whose technology is positioned to leverage the EHDS—facilitating safe, compliant cross-border data exchange—gain a strategic advantage in developing and training robust AI models.

4. Buyer Dynamics

Private Equity (PE): PE firms continue to pay a structural premium, offering a median EV/EBITDA multiple of approximately 11.2x in Europe for desirable, scalable assets, largely due to capital deployment pressure and financial structuring.

Strategic (Corporate) Buyers: Large Pharma, MedTech, and Hospital systems are driving M&A primarily through a "string-of-pearls" consolidation strategy to acquire specific capabilities (like AI diagnostics or advanced analytics), even if at a lower median multiple (~8.5x EV/EBITDA) than PE, as they account for expected internal synergies.

To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email [email protected]